Concord Biotech Ltd IPO Timeline

Concord Biotech Ltd IPO opens on 04-Aug-2023, and closes on 08-Aug-2023. The Concord Biotech Ltd IPO bid date is from 04-Aug-2023 to 08-Aug-2023. The Cut-off time for UPI Mandate confirmation is 12 P.M. on the next day of issue closing day.

Event Date
Concord Biotech Ltd IPO Opening Date 04-Aug-2023
Concord Biotech Ltd IPO Closing Date 08-Aug-2023
Basis of Allotment 11-Aug-2023
Initiation of Refunds 14-Aug-2023
Credit of Shares to Demat 17-Aug-2023
Concord Biotech Ltd IPO Listing Date 18-Aug-2023

Concord Biotech Ltd IPO Lot Size

Concord Biotech Ltd IPO lot size is 20 shares. A retail-individual investor can apply for up to 13 lots (260 shares or 192660).

Application Lots Shares Amount
Minimum 1 20 ₹14820
Maximum 13 260 ₹192660

Concord Biotech Ltd IPO Details

Concord Biotech Ltd IPO Date 04-Aug-2023 to 08-Aug-2023
Concord Biotech Ltd IPO Face Value Shares of ₹1 per share
Concord Biotech Ltd IPO Price ₹705 to ₹741 per share
Concord Biotech Ltd IPO Lot Size 20
Issue Size Shares of ₹1 (aggregating up to ₹1550.52 Cr)
Fresh Issue -
Offer for Sale Shares of ₹1 (aggregating up to ₹1475.26 Cr)
Issue Type Book Built Portion
Listing At BSE, NSE
QIB Shares Offered Not more than 4183130
Retail Shares Offered Not less than 7320479
NII (HNI) Shares Offered Not less than 3137348
Company Promoters Sudhir Vaid, Ankur Vaid.

Objects of the Issue

The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

  • 1 Listing the Equity Shares on the Stock Exchanges

Company Financials

Concord Biotech Ltd Financial Information (Restated)

Period Ended Total Assets Total Revenue Profit After Tax
03-2023 1514.65 888.48 238.13
03-2022 1313.46 736.35 178.57
03-2021 1182.84 630.75 235.33
Amount in ₹ Crore
  • Established presence across the complex fermentation value chain.
  • Global leadership in immunosuppressant APIs along with a wide spectrum of complex fermentation-based APIs across multiple therapeutic areas.
  • Scaled manufacturing facilities with a consistent regulatory compliance track record and supported by strong R&D capabilities.
  • Diversified global customer base with long-standing relationships with key customers.
  • Experienced Promoters, management team supported by marquee investors.
  • Financial track record of rapid growth and consistent profitability with healthy cash flows and shareholder returns.
  • Any delay, interruption or reduction in the supply of its raw materials or the transportation of the company raw materials or products may adversely impact the pricing and supply of its products and have an adverse effect on its business.
  • Any manufacturing or quality control issues may damage its reputation, subject it to regulatory action, and expose the company to litigation or other liabilities, which could adversely affect its business, financial condition and results of operations.
  • A slowdown or shutdown in its manufacturing or research and development operations, all located in Gujarat, India, could adversely affect the company business, financial condition and results of operations.
  • The company depends on a limited number of key customers for a substantial portion of its revenues. Any significant reduction in demand for the company products from such customers may adversely affect its business and results of operations.
  • If the company is unable to obtain trademarks and patents for its products or protect such proprietary information, or inadvertently infringe on the patents of others, its business may be adversely affected.
  • The company is subject to extensive government regulations, and if its fail to obtain, maintain or renew the company statutory and regulatory licenses, permits and approvals required for its business operations, the company business, financial condition, results of operations and cash flows may be adversely affected.
  • The company inability to accurately forecast demand for its products, manage it inventory and utilize the company manufacturing capacity optimally may have an adverse effect on its business, financial condition, results of operations and cash flows.
  • Pricing pressure from customers may affect the company ability to maintain or increase its product prices and, in turn, the company revenue from product sales, gross margin and profitability, which may adversely affect its business, financial condition and results of operations.
  • The company had significant working capital requirements. If its experience insufficient cash flows to fund the company working capital requirements, there may be an adverse effect on its business, cash flows and results of operations.
  • The company is currently entitled to certain incentive schemes. Any decrease in or discontinuation in such schemes may affect the company results of operations.
  • There are outstanding legal proceedings involving the Company.
  • Certain therapeutic areas contribute to a more significant portion of its total revenue, and the company business, prospects, results of operations and financial condition may be adversely affected if its products in these therapeutic areas do not perform according to the projections of its business plans or if competing products become available and gain wider market acceptance.
  • The company success depends on its ability to develop and commercialize new products in a timely manner. If the company research and development efforts do not succeed or the products its commercialize do not perform as expected, this may hinder the introduction of new products, and could adversely affect its business, financial condition and results of operations.
  • The company inability to successfully implement its business plan, domestic and international expansion plans and growth strategies could have an adverse effect on its business, financial condition, results of operations and cash flows.
  • If the company do not maintain and increase the number of its arrangements for the marketing and distribution of the company products, its business, financial condition and results of operations could be adversely affected.
  • The company international operations expose it to complex management, legal, tax and economic risks, which could adversely affect the company business, financial condition and results of operations.
  • The COVID-19 pandemic, or any future pandemic or widespread public health emergency, could adversely impact its business, financial condition, cash flows and results of operations.
  • The pharmaceutical industry in which the company operate is highly competitive. If its cannot respond adequately to the competition the company expect to face, its will lose market share and the company profits will decline, which will adversely affect its business, financial condition and results of operations.
  • Non-compliance with and changes in environmental, health and safety, and labor laws and other applicable regulations may adversely affect its business, financial condition, results of operations and cash flows.
  • The company is subject to the risk of loss due to fire, accidents and other hazards as its R&D and manufacturing processes and materials are highly flammable and hazardous. The company also subject to the risk of other natural calamities or general disruptions affecting its production facilities and distribution chain.
  • The company is exposed to counterparty credit risk and any delay in receiving payments or non-receipt of payments may adversely impact its business and results of operations.
  • Its inability to attract or retain companies who are looking to it for in-licensing in the future could adversely affect its market share. If the covenants in the company agreements with such companies are onerous or commercially-restrictive, its results of operations and financial condition could be adversely affected.
  • The company enter into out-licensing arrangements for the distribution of its products in certain geographies.
  • If third parties on whom its relies for clinical trials (including bio-equivalence studies) do not perform their obligations as contractually required or as the company expect, or do not comply with the relevant Current Good Manufacturing Practices (cGMP) or other applicable regulations, its may not be able to obtain regulatory approval for or commercialize the company formulations products.
  • Delay or failure in the performance of its contracts may adversely affect the company business, financial condition and results of operations.
  • Its success depends on the company ability to retain and attract qualified senior management and other key personnel, and if the company not able to retain them or recruit additional qualified personnel, its may be unable to successfully develop the company business.
  • The availability of counterfeit drugs, such as drugs passed off by others as its products, could adversely affect the company goodwill and results of operations.
  • Its inability to meet the company obligations, including financial and other covenants under the company debt financing arrangements could adversely affect its business, financial condition, results of operations and cash flows.
  • The company currently relies extensively on its systems including information technology systems and products processing/quality assurance systems and their failure could adversely affect its manufacturing operations.
  • Changes in technology may render its current technologies obsolete or require it to make substantial capital investments.
  • The company insurance coverage may not be sufficient or adequate to cover its losses or liabilities. If the company suffer a large uninsured loss or if its suffer an insured loss that significantly exceeds the company insurance coverage, its financial condition and results of operations may be adversely affected.
  • The company has in the past entered into related-party transactions and may continue to do so in the future.
  • The company is subject to risks arising from exchange rate fluctuations.
  • The company will be controlled by its Promoters so long as they hold a majority of the Equity Shares, which will allow them to influence the outcome of certain matters submitted for approval of its Shareholders and their interests may differ from those of the other Shareholders.
  • The company Directors and key management personnel may have interests in the Company in addition to reimbursement of expenses incurred and receipt of remuneration from the Company.
  • Information relating to the manufacturing capacity, actual production and capacity utilization of its manufacturing facilities included in this Draft Red Herring Prospectus are based on various assumptions and estimates and future production and capacity may vary.
  • Its ability to pay dividends in the future will depend on the company earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of its financing arrangements.
  • The company do not own its Corporate Office and its warehouses.
  • The company has contingent liabilities and capital commitments. Its financial condition could be adversely affected if any of these contingent liabilities or capital commitments materialize.
  • This Draft Red Herring Prospectus contains information from third parties, including an industry report prepared by an independent third-party research agency, Frost & Sullivan (India) Private Limited (F&S) which the company has commissioned and paid for purposes of confirming its understanding of the industry exclusively in connection with the Offer.
  • Fluctuations in the market value of its investments could adversely affect the company results of operations and financial condition.
  • The company operations are labor intensive and its may be subject to strikes, work stoppages or increased wage demands by the company employees or those of its suppliers.
  • Certain non-GAAP measures and other statistical information relating to its operations and financial performance have been included in this Draft Red Herring Prospectus. These non-GAAP measures are not measures of operating performance or liquidity defined by Ind AS and may not be comparable with those presented by other companies.
  • Continue to increase our API market share and further develop its portfolio of complex and niche APIs with high growth potential.
  • Increase the presence of its existing formulations and expand into new formulations.
  • Improve cost management and operational efficiencies.
  • Grow its CDMO business.

Concord Biotech Ltd IPO Promoter Holding

Pre Issue Share Holding 29.40%
Post Issue Share Holding 29.40%

Concord Biotech Ltd IPO Subscription Status (Bidding Detail)

The Concord Biotech Ltd IPO is subscribed 24.87 times on Aug 08, 2023 05:00:00 PM. The public issue subscribed 3.78 times in the retail category, 67.67 times in the QIB category, and 16.99 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category QIB NII Retail Employee Total
Subscription (times) 67.67 16.99 3.78 24.48 24.87

Concord Biotech Ltd IPO Prospectus

Concord Biotech Ltd IPO Listing Date

Listing Date 18 Aug 23
BSE Script 543960
NSE Symbol CONCORDBIO
Listing In BSE, NSE
ISIN INE338H01029
IPO Price ₹741
Face Value ₹1

Concord Biotech Ltd IPO Registrar

Link Intime India Pvt Ltd

Phone: +91 810 811 4949
Email: concordbiotech.ipo@linkintime.co.in
Website: www.linkintime.co.in

Concord Biotech Ltd IPO Lead Manager(s)

  1. Kotak Mahindra Capital Company Ltd
  2. Citigroup Global Markets India Pvt Ltd
  3. Jeffries India Pvt Ltd

FAQs on Concord Biotech Ltd IPO

Concord Biotech Ltd IPO, which opens for subscription from 04-Aug-2023 to 08-Aug-2023 has an issue size of ₹1550.52 crore. The issue type is book building issue.

In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for Concord Biotech Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.

Concord Biotech Ltd IPO Opens for subscription from 04-Aug-2023 to 08-Aug-2023.

The lot size of Concord Biotech Ltd is 20 shares. Retail investors can subscribe to minimum 1 lot and maximum 13 lots. The minimum and maximum application value is ₹14820 and ₹192660 respectively.

Allotment date for Concord Biotech Ltd is 11-Aug-2023 and refund of application amount (in case allotment is not received) will begin from 14-Aug-2023. If your allotment goes through, then shares will be credited in your Demat account by 17-Aug-2023.

The registrar for Concord Biotech Ltd IPO is Link Intime India Pvt Ltd. You can check your IPO allotment status on the registrar's website.

The shares of Concord Biotech Ltd are proposed to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Power your investments with our smart trading platforms

mobilefooterimg
  • app_download_icon_img
    5 million+
    App downloads
  • 1_Click_icon_img
    1-Click
    Order Placement
  • higherreturns_icon_img
    2,361 Crore+
    Average Daily Turnover
Download App